FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

The summary for the FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.

FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed): The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually to exchange information and explore a defined subject, issue, or area of concern impacting the public's health within the scope of the FDA's mission. Support of such meetings is contingent upon the fiscal and programmatic interests and priorities of the FDA's respective Offices and Centers. Therefore, a conference grant application is required to contain an advance permission-to-submit letter from one of the participating FDA Centers listed under Components of Participating Organizations. Advanced Permission to Submit an Application: A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date. To request advanced permission to submit an application letter from one of the participating FDA Centers/Offices, applicants must submit the following information on applicant organizational letterhead: FOA Number and Title; Selected application due date; FDA Center/Office that the application is seeking advanced permission to apply to; Meeting/conference title; Location and date of proposed meeting/conference; Names, Address, Telephone number and email address of Institution(s) participating in the application; Name, Address, Telephone number and email address of the Principal Investigator/Project Director; Names of other key personnel (if any) and points of contact; Number of anticipated attendees; Purpose, benefit, objectives and/or justification of the meeting/conference and how it aligns with the mission and program priorities of the targeted FDA Center/Office; Estimated budget that will be requested for the meeting/conference and purpose; and List other sources of funding (secured and planned), if applicable. All advanced permission to submit an application requests must be submitted via email to the Grants Management Contact listed in Section VII. Agency Contacts of this FOA. Applicants are urged to initiate contact well in advance of the chosen application due date and no later than 8 weeks before that date. Advanced permission to submit an application requests received after 8 weeks prior to the selected application due date will not be accepted. Please note that agreement to accept an application does not guarantee funding or funding at the level requested. Consistent with Federal civil rights laws, it is expected that organizers of FDA-supported conferences and scientific meetings take steps to maintain a safe and respectful environment for all attendees by providing an environment free from discrimination and harassment, sexual or otherwise.